

## **ABRIDGED CONSOLIDATED INTERIM FINANCIAL STATEMENTS FOR THE FIRST HALF-YEAR 2010**

**Fornix BioSciences N.V.**

## ABRIDGED CONSOLIDATED INCOME STATEMENT

|  | 2010<br>1-1 to 30-6<br>Continued<br>business<br>activities | 2010<br>1-1 to 30-6<br>Discontinued<br>business<br>activities | 2010<br>1-1 to 30-6<br>Total | 2009<br>1-1 to 30-6<br>Continued<br>business<br>activities | 2009<br>1-1 to 30-6<br>Discontinued<br>business<br>activities | 2009<br>1-1 to 30-6<br>Total |
|--|--|---|------------------------------|--|---|------------------------------|
| Income   | 5,062  | 12,555  | 17,617                       | 5,639  | 13,257  | 18,896                       |
| Cost of sales                                    | 2,043  | 1,126   | 3,169                        | 2,212  | 1,221   | 3,433                        |
| <b>Gross result</b>                              | <b>3,019</b>   | <b>11,429</b>   | <b>14,448</b>                | <b>3,427</b>   | <b>12,036</b>   | <b>15,463</b>                |
| <b>Other Income</b>                              | -  | -   | -                            | <b>28</b>  | <b>16</b>   | <b>44</b>                    |
| Distribution costs                               | 222  | 435   | 657                          | 239  | 534   | 773                          |
| Personnel costs                                  | 2,313  | 1,814   | 4,127                        | 2,024  | 1,951   | 3,975                        |
| Travel expenses                                  | 273  | 397   | 670                          | 247  | 446   | 693                          |
| Depreciation and amortisation                    | 172  | 31  | 203                          | 134  | 137   | 271                          |
| Accommodation costs                              | 77   | 76  | 153                          | 78   | 80  | 158                          |
| Research and development costs                   | 14   | 711   | 725                          | 23   | 1,666   | 1,689                        |
| Quality control costs                            | -  | 100   | 100                          | 2  | 227   | 229                          |
| Production and warehouse costs                   | 11   | 70  | 81                           | 6  | 75  | 81                           |
| General overheads                                | (418)  | 1,617   | 1,199                        | 410  | 1,332   | 1,742                        |
| Charged on to production and trading inventories | -  | (618)   | (618)                        | -  | (700)   | (700)                        |
| <b>Sum of the costs</b>                          | <b>2,664</b>   | <b>4,633</b>  | <b>7,297</b>                 | <b>3,163</b>   | <b>5,748</b>  | <b>8,911</b>                 |
| <b>Result from operating activities</b>          | <b>355</b>   | <b>6,796</b>  | <b>7,151</b>                 | <b>292</b>   | <b>6,304</b>  | <b>6,596</b>                 |
| Net financing income/expenses                    | 339  | (3)   | 336                          | 449  | 24  | 473                          |
| <b>Profit before taxation</b>                    | <b>694</b>   | <b>6,793</b>  | <b>7,487</b>                 | <b>741</b>   | <b>6,328</b>  | <b>7,069</b>                 |
| Tax on profits                                   | 165  | 1,607   | 1,772                        | 195  | 1,666   | 1,861                        |
| <b>Profit for the financial period</b>           | <b>529</b>   | <b>5,186</b>  | <b>5,715</b>                 | <b>546</b>   | <b>4,662</b>  | <b>5,208</b>                 |
| Attributable to:                                 |  |   |                              |  |   |                              |
| Shareholders of the parent company               | 529  | 5,186   | 5,715                        | 546  | 4,662   | 5,208                        |
| Minority interest                                | -  | -   | -                            | -  | -   | -                            |
| <b>Profit for the financial period</b>           | <b>529</b>   | <b>5,186</b>  | <b>5,715</b>                 | <b>546</b>   | <b>4,662</b>  | <b>5,208</b>                 |
| Ordinary earnings per share (x €)                | 0.07   | 0.67  | 0.74                         | 0.07   | 0.62  | 0.69                         |
| Diluted earnings per share (x €)                 | 0.07   | 0.67  | 0.74                         | 0.07   | 0.62  | 0.69                         |

**ABRIDGED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME**

|   | <b>2010</b>           | <b>2009</b>           |
|---|-----------------------|-----------------------|
|   | <b>01-01 to 30-06</b> | <b>01-01 to 30-06</b> |
| Profit for the financial period   | 5,715                 | 5,208                 |
| Other comprehensive income  | -                     | -                     |
| <b>Other comprehensive income for the financial period, net of income tax</b> | <b>-</b>              | <b>-</b>              |
| <b>Total comprehensive income for the financial period</b>                    | <b>5,715</b>          | <b>5,208</b>          |
| Attributable to:  |                       |                       |
| Shareholders of the parent company  | 5,715                 | 5,208                 |
| Minority interest   | -                     | -                     |
| <b>Total comprehensive income for the financial period</b>                    | <b>5,715</b>          | <b>5,208</b>          |

**ABRIDGED CONSOLIDATED BALANCE SHEET**

(before allocation of the result)

|  | 30-06-2010    | 31-12-2009    | 30-6-2009     |
|--|---------------|---------------|---------------|
| <b>ASSETS</b>  |               |               |               |
| <b>Non-current assets</b>  |               |               |               |
| Intangible assets  | 13,250        | 13,307        | 13,716        |
| Property, plant and equipment  | 1,855         | 3,135         | 3,178         |
| Deferred tax assets  | 24            | 91            | 80            |
| <b>Total Non-current assets</b>  | <b>15,129</b> | <b>16,533</b> | <b>16,974</b> |
| <b>Current assets</b>  |               |               |               |
| Inventories  | 1,354         | 4,294         | 4,020         |
| Trade and other receivables  | 2,113         | 5,206         | 5,462         |
| Cash and cash equivalents  | 16,815        | 35,158        | 33,545        |
| Assets held for sale   | 7,191         | -             | -             |
| <b>Total Current assets</b>  | <b>27,473</b> | <b>44,658</b> | <b>43,027</b> |
| <b>Total Assets</b>  | <b>42,602</b> | <b>61,191</b> | <b>60,001</b> |
| <b>EQUITY AND LIABILITIES</b>  |               |               |               |
| <b>Shareholders' equity</b>  |               |               |               |
| Paid-up and called-up share capital  | 1,208         | 1,208         | 1,178         |
| Share premium  | 32,373        | 35,053        | 33,750        |
| Other reserves   | (2,496)       | 7,499         | 12,653        |
| Profit for the financial period  | 5,715         | 11,049        | 5,208         |
| <b>Total Shareholders' equity attributable to shareholders of the parent Company</b> | <b>36,800</b> | <b>54,809</b> | <b>52,789</b> |
| Minority interest  | 1             | 1             | 1             |
| <b>Total Shareholders' equity</b>  | <b>36,801</b> | <b>54,810</b> | <b>52,790</b> |
| <b>Non-current liabilities</b>   |               |               |               |
| Employee benefits  | 18            | 40            | 38            |
| Deferred tax liabilities   | 268           | 254           | 241           |
| <b>Total Non-current liabilities</b>   | <b>286</b>    | <b>294</b>    | <b>279</b>    |
| <b>Current liabilities</b>   |               |               |               |
| Trade payables   | 522           | 1,316         | 1,537         |
| Taxes payable  | 402           | 646           | 1,029         |
| Other items to be paid   | 3,068         | 4,125         | 4,366         |
| Liabilities held for sale  | 1,523         | -             | -             |
| <b>Total Current liabilities</b>   | <b>5,515</b>  | <b>6,087</b>  | <b>6,932</b>  |
| <b>Total Equity and liabilities</b>  | <b>42,602</b> | <b>61,191</b> | <b>60,001</b> |

**ABRIDGED CONSOLIDATED CASH FLOW STATEMENT**

|  | <b>2010</b>           | <b>2009</b>           |
|--|-----------------------|-----------------------|
|  | <b>01-01 to 30-06</b> | <b>01-01 to 30-06</b> |
| <b>Cash flow from operating activities</b>         |                       |                       |
| Receipts from customers                            | 19,155                | 20,866                |
| Payments to suppliers and employees                | (12,642)              | (15,435)              |
| Net cash flow from business operations             | 6,513                 | 5,431                 |
| Interest received                                  | 253                   | 1,627                 |
| Interest paid                                      | -                     | (1)                   |
| Tax paid on profits                                | (1,749)               | (776)                 |
| Grants received                                    | -                     | 175                   |
| Cash flow from other operating activities          | (1,496)               | 1,025                 |
| <b>Net cash flow from operating activities</b>     | <b>5,017</b>          | <b>6,456</b>          |
| <b>Cash flow from investing activities</b>         |                       |                       |
| Investments in intangible assets                   | (6)                   | -                     |
| Investments in property, plant and equipment       | (140)                 | (361)                 |
| <b>Net cash flow from investing activities</b>     | <b>(146)</b>          | <b>(361)</b>          |
| <b>Cash flow from financing activities</b>         |                       |                       |
| Dividend paid                                      | (23,195)              | (4,571)               |
| <b>Net cash flow from financing activities</b>     | <b>(23,195)</b>       | <b>(4,571)</b>        |
| Net decrease/increase in cash and cash equivalents | (18,324)              | 1,524                 |
| Cash and cash equivalents at 1 January             | 35,158                | 32,021                |
| Cash and cash equivalents held for sale            | (19)                  | -                     |
| <b>Cash and cash equivalents at 30 June</b>        | <b>16,815</b>         | <b>33,545</b>         |

## ABRIDGED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

|  | Paid-up and<br>called-up<br>share capital | Share<br>premium | Shares<br>in<br>treasury | Retained<br>earnings | Total other<br>reserves | Profit for the<br>financial<br>period | Total          |
|--|---|------------------|--------------------------|----------------------|-------------------------|---------------------------------------|----------------|
| <b>Balance at 1 January 2009</b>                               | <b>1,157</b>                              | <b>32,896</b>    | <b>(2,496)</b>           | <b>10,090</b>        | <b>7,594</b>            | <b>10,265</b>                         | <b>51,912</b>  |
| <b>Total comprehensive income<br/>for the financial period</b> |   |                  |                          |                      |                         |                                       |                |
| Profit for the first half-year 2009                            | -   | -                | -                        | -                    | -                       | 5,208                                 | 5,208          |
| Appropriation of 2008 result                                   | -   | -                | -                        | 4,818                | 4,818                   | (4,818)                               | -              |
| <b>Total comprehensive income<br/>for the financial period</b> | <b>-</b>                                  | <b>-</b>         | <b>-</b>                 | <b>4,818</b>         | <b>4,818</b>            | <b>390</b>                            | <b>5,208</b>   |
| <b>Transactions with shareholders<br/>in equity</b>            |   |                  |                          |                      |                         |                                       |                |
| Dividend payment 2008  | 21  | 854              | -                        | -                    | -                       | (5,447)                               | (4,572)        |
| Cost of share ownership plan                                   | -   | -                | -                        | 241                  | 241                     | -                                     | 241            |
| <b>Total transactions with<br/>shareholders</b>                | <b>21</b>                                 | <b>854</b>       | <b>-</b>                 | <b>241</b>           | <b>241</b>              | <b>(5,447)</b>                        | <b>(4,331)</b> |
| <b>Balance at 30 juni 2009</b>                                 | <b>1,178</b>                              | <b>33,750</b>    | <b>(2,496)</b>           | <b>15,149</b>        | <b>12,653</b>           | <b>5,208</b>                          | <b>52,789</b>  |
| <b>Total comprehensive income<br/>for the financial period</b> |   |                  |                          |                      |                         |                                       |                |
| Profit for the second half-year 2009                           | -   | -                | -                        | -                    | -                       | 5,841                                 | 5,841          |
| <b>Total comprehensive income<br/>for the financial period</b> | <b>-</b>                                  | <b>-</b>         | <b>-</b>                 | <b>-</b>             | <b>-</b>                | <b>5,841</b>                          | <b>5,841</b>   |
| <b>Transactions with shareholders<br/>in equity</b>            |   |                  |                          |                      |                         |                                       |                |
| Interim dividend 2009  | 27  | 1,303            | -                        | (4,866)              | (4,866)                 | -                                     | (3,536)        |
| Cost of share ownership plan                                   | -   | -                | -                        | (288)                | (288)                   | -                                     | (288)          |
| Issue of shares in the context of<br>the share ownership plan  | 3   | -                | -                        | -                    | -                       | -                                     | 3              |
| <b>Total transactions with<br/>shareholders</b>                | <b>30</b>                                 | <b>1,303</b>     | <b>-</b>                 | <b>(5,154)</b>       | <b>(5,154)</b>          | <b>-</b>                              | <b>(3,821)</b> |
| <b>Balance at 31 december 2009</b>                             | <b>1,208</b>                              | <b>35,053</b>    | <b>(2,496)</b>           | <b>9,995</b>         | <b>7,499</b>            | <b>11,049</b>                         | <b>54,809</b>  |

|  | Paid-up and<br>called-up<br>share capital | Share<br>premium | Shares<br>in<br>treasury | Retained<br>earnings | Total other<br>reserves | Profit for the<br>financial<br>period | Total           |
|--|---|------------------|--------------------------|----------------------|-------------------------|---------------------------------------|-----------------|
| <b>Balance at 31 december 2009</b>                         | <b>1,208</b>                              | <b>35,053</b>    | <b>(2,496)</b>           | <b>9,995</b>         | <b>7,499</b>            | <b>11,049</b>                         | <b>54,809</b>   |
| <b>Total comprehensive income for the financial period</b> |   |                  |                          |                      |                         |                                       |                 |
| Profit for the first half-year 2010                        | -   | -                | -                        | -                    | -                       | 5,715                                 | 5,715           |
| Appropriation of 2009 result                               | -   | -                | -                        | 11,049               | 11,049                  | (11,049)                              | -               |
| <b>Total comprehensive income for the financial period</b> | <b>-</b>                                  | <b>-</b>         | <b>-</b>                 | <b>11,049</b>        | <b>11,049</b>           | <b>(5,334)</b>                        | <b>5,715</b>    |
| <b>Transactions with shareholders in equity</b>            |   |                  |                          |                      |                         |                                       |                 |
| Dividend payment 2009                                      | -   | -                | -                        | (6,031)              | (6,031)                 | -                                     | (6,031)         |
| Special dividend payment                                   | -   | (2,680)          | -                        | (14,484)             | (14,484)                | -                                     | (17,164)        |
| Cost of share ownership plan                               | -   | -                | -                        | (529)                | (529)                   | -                                     | (529)           |
| <b>Total transactions with shareholders</b>                | <b>-</b>                                  | <b>(2,680)</b>   | <b>-</b>                 | <b>(21,044)</b>      | <b>(21,044)</b>         | <b>-</b>                              | <b>(23,724)</b> |
| <b>Balance at 30 juni 2010</b>                             | <b>1,208</b>                              | <b>32,373</b>    | <b>(2,496)</b>           | <b>-</b>             | <b>(2,496)</b>          | <b>5,715</b>                          | <b>36,800</b>   |

## Notes to the abridged consolidated interim financial statements

### 1 General

The abridged consolidated interim financial statements for the first half-year 2010 from Fornix BioSciences N.V. (the "Company") include the Company and its subsidiaries (together referred to as the "Group").

The abridged consolidated interim financial statements were prepared by the Board of Directors and released for publication on 27 July 2010.

### 2 Statement of compliance

The abridged consolidated interim financial statements have been prepared in accordance with International Financial Reporting Standards (IFRS), as adopted within the European Union, and the interpretations of the International Accounting Standards Board, hereinafter referred to as IFRS. The abridged consolidated interim financial statements have been prepared in accordance with IAS 34 "Interim Financial Reporting".

### 3 Basis of preparation

The abridged consolidated interim financial statements are presented in thousands of euros, unless stated otherwise.

For the year 2010 no important changes occurred with regard to the accounting principles of the Group so please see the 2009 Annual accounts for the principals of valuation and profit calculation.

### 4 New standards and interpretations

The most relevant new standards, changes to standards and interpretations that became effective in 2010, are stated below:

- *Revised IFRS 3 Business Combinations* incorporates the following changes that are likely to be relevant to the Group's operations:
  - Contingent consideration will be measured at fair value, with subsequent changes therein recognised in profit or loss.
  - Transactions costs, other than share and debt issue costs, will be expensed as incurred.
- *Amended IAS 27 Consolidated and separate Financial Statements* requires accounting for changes in ownership interests by the Group in a subsidiary, while maintaining control, to be recognised as an equity transaction. When the Group loses control of a subsidiary, any interest retained in the former subsidiary will be measured at fair value with the gain or loss recognised in the income statement.
- *IAS 39 Financial instruments: Recognition and Measurement - eligible hedged items*, which clarifies the existing principles that determine whether specific risk or portions of cash flows are eligible for designation in a hedging relationship.

These new standards apply to the abridged consolidated interim financial statements for the first half-year 2010.

### 5 Use of estimates and judgements

The preparation of the abridged consolidated interim financial statements requires the Board of Directors of the Company to form judgements, estimates and assumptions that affect the application of accounting policies and the reported values of assets and liabilities and of income and expenses. The actual outcomes may differ from these estimates.

## 6 Segmented information

The Group's activities can be broken down by segment as follows:

|  | <i>First half-year 2010</i> | <i>First half-year 2009</i> |
|--|-----------------------------|-----------------------------|
| <b>Division Allergy</b>  |                             |                             |
| Income   | 12,707                      | 13,494                      |
| Gross result   | 11,429                      | 12,036                      |
| Other income   | -                           | 16                          |
| Sum of the costs <sup>1)</sup>   | 4,633                       | 5,748                       |
| Result from operating activities <sup>1)</sup>   | 6,796                       | 6,304                       |
| Total depreciation and amortisation<br>(intangible assets and property, plant and equipment) | 31                          | 136                         |
| Capital employed<br>(non-current assets and working capital)                                 | 6,012                       | 6,461                       |
| Total investments (intangible assets and property, plant and equipment)                      | 29                          | 127                         |
| Total liabilities  | 1,304                       | 2,658                       |
| Number of employees (average FTEs)   | 63.7                        | 68.3                        |
| <b>Artu Biologicals Deutschland</b>  |                             |                             |
| Income   | 954                         | 1,252                       |
| Gross result   | 692                         | 906                         |
| Other income   | -                           | -                           |
| Sum of the costs <sup>1)</sup>   | 827                         | 923                         |
| Result from operating activities <sup>1)</sup>   | (135)                       | (17)                        |
| Total depreciation and amortisation<br>(intangible assets and property, plant and equipment) | 55                          | 29                          |
| Capital employed<br>(non-current assets and working capital)                                 | 2,692                       | 3,199                       |
| Total investments (intangible assets and property, plant and equipment)                      | 91                          | 77                          |
| Total liabilities  | 865                         | 1,183                       |
| Number of employees (average FTEs)   | 11.8                        | 7.3                         |
| <b>Division Medical Aids</b>   |                             |                             |
| Income   | 4,108                       | 4,387                       |
| Gross result   | 2,327                       | 2,521                       |
| Other income   | -                           | -                           |
| Sum of the costs <sup>1)</sup>   | 1,259                       | 1,442                       |
| Result from operating activities <sup>1)</sup>   | 1,068                       | 1,079                       |
| Total depreciation and amortisation<br>(intangible assets and property, plant and equipment) | 55                          | 52                          |
| Capital employed<br>(non-current assets and working capital)                                 | 13,731                      | 14,061                      |
| Total investments (intangible assets and property, plant and equipment)                      | 18                          | 13                          |
| Total liabilities  | 634                         | 612                         |
| Number of employees (average FTEs)   | 15.2                        | 22.4                        |
| <b>Elimination</b>   |                             |                             |
| Income   | (152)                       | (237)                       |

|  | <i>First half-year 2010</i> | <i>First half-year 2009</i> |
|--|-----------------------------|-----------------------------|
| <b>Other</b>   |                             |                             |
| Income   | -                           | -                           |
| Gross result   | -                           | -                           |
| Other income   | -                           | 28                          |
| Sum of the costs <sup>1)</sup>   | 578                         | 798                         |
| Result from operating activities <sup>1)</sup>   | (578)                       | (770)                       |
| Total depreciation and amortisation<br>(intangible assets and property, plant and equipment) | 62                          | 54                          |
| Capital employed<br>(non-current assets and working capital)                                 | 382                         | (87)                        |
| Total investments (intangible assets and property, plant and equipment)                      | 358                         | 144                         |
| Total liabilities  | 2,779                       | 2,758                       |
| Number of employees (average FTEs)   | 11.2                        | 12.2                        |
| <b>Total</b>   |                             |                             |
| Income   | 17,617                      | 18,896                      |
| Gross result   | 14,448                      | 15,463                      |
| Other income   | -                           | 44                          |
| Sum of the costs <sup>1)</sup>   | 7,297                       | 8,911                       |
| Result from operating activities <sup>1)</sup>   | 7,151                       | 6,596                       |
| Total depreciation and amortisation<br>(intangible assets and property, plant and equipment) | 203                         | 271                         |
| Capital employed<br>(non-current assets and working capital)                                 | 22,817                      | 23,634                      |
| Total investments (intangible assets and property, plant and equipment)                      | 496                         | 361                         |
| Total liabilities  | 5,582                       | 7,211                       |
| Number of employees (average FTEs)   | 101.9                       | 110,2                       |

<sup>1)</sup> The holding company Fornix BioSciences N.V. has allocated € 1,520 (2009: € 872) to the Allergy Division, Artu Biologicals Deutschland and The Division Medical Aids of its sum of the costs of € 2,098 (2009: € 1,670). The allocated amounts relate to the directly attributable costs of Fornix BioSciences to the segments. For 2010, € 1,328 (2009:€ 702) was allocated to the Allergy Division, € 12 (2009: € 12) to Artu Biologicals Deutschland and € 180 (2009: € 158) to the Division Medicals Aids.

## 7 Discontinued business activities

The Group sold the Dutch Allergy Division, Artu Biologicals Europe B.V. and Artu Biologicals Onroerend Goed B.V., at July 1, 2010. The Board of Directors decided to sell the Dutch Allergy Division because of , as frequently communicated by Fornix, the uncertainty surrounding obtainment of the required registration for Oralgen® Grass Pollen and the consequences of the registration status for the reimbursement by Health insurance company's of the Oralgen® products.

The results for 2009 and 2010 to the aforementioned are in accordance with IFRS 5 'Non-current assets held for sale and discontinued operations', and are classified as discontinued business activities.

|                               | <b>30 June 2010</b> | <b>30 June 2009</b> |
|-------------------------------|---------------------|---------------------|
| <b>Assets held for sale</b>   |                     |                     |
| Intangible assets             | 16                  | -                   |
| Property, plant and equipment | 1,264               | -                   |
| Inventories                   | 2,637               | -                   |
| Trade and other receivables   | 3,255               | -                   |
| Cash and cash equivalents     | 19                  | -                   |
|                               | <b>7,191</b>        | <b>-</b>            |

|                                  | 30 June 2010 | 30 June 2009 |
|----------------------------------|--------------|--------------|
| <b>Liabilities held for sale</b> |              |              |
| Non-current liabilities          | 75           | -            |
| Trade and other payables         | 1,448        | -            |
|                                  | <b>1,523</b> | -            |

## 8 Tax position

A total of € 1,772 tax on profits is due on the result of the first half-year of 2010 (first half-year of 2009: € 1,861). As at 30 June 2010, the tax amounts to € 200 payable. End of June 2009 the tax amounts to € 744 as receivable.

All companies with the exception of Artu Biologicals Deutschland GmbH & Co KG, Artu Biologicals Deutschland Verwaltungs GmbH and Artu Biologicals S.L. are part of the Fornix BioSciences N.V. tax entity. The loss of Artu Biologicals Deutschland GmbH & Co KG, however, fully belongs to the fiscal entity. The Dutch applicable tax rate amounts to 25.5%. The effective tax rate for the first half-year of 2010 is 23.7% (first half-year of 2009: 26.3%).

## 9 Ordinary earnings per share and diluted earnings per share

|   | <i>First half-year 2010</i> | <i>First half-year 2009</i> |
|---|-----------------------------|-----------------------------|
| <b>Ordinary earnings per share</b>  |                             |                             |
| Profit after taxation   | 5,715                       | 5,208                       |
| Weighted average number of ordinary shares (x 1,000)  | 7,732                       | 7,541                       |
| Ordinary earnings per share (in €)  | 0.74                        | 0.69                        |
| <b>Diluted earnings per share</b>   |                             |                             |
| Profit after taxation   | 5,715                       | 5,208                       |
| Weighted average number of shares for the calculation of the diluted earnings per share (x 1,000) | 7,732                       | 7,541                       |
| Diluted earnings per share (in €)   | 0.74                        | 0.69                        |

## 10 Dividend

In May 2010 the final dividend 2009, an amount of € 6,031 was settled. In May 2010 also a special dividend, charged to the freely distributable reserves, of € 17,164 was settled. The final dividend as well as the special dividend was paid fully in cash. The accompanying dividend tax was paid in June of 2010.